Review
Aug 2026
The landscape of genetic medicines for in vivo T cell reprogramming.
Key challenges related to the biodistribution, activation, and persistence of modified T cells are highlighted, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond.
Jens B. Simonsen, Viktor Lemgart, J. Kulkarni et al.
· Advanced Drug Delivery Revie... · 0 citations